Klinicheskie i biokhimicheskie aspekty issledovaniya insulinonodobnogo faktora rosta-1 v syvorotke krovi u retsipientov s narusheniyami kostnogo obmena posle peresadki serdtsa i pochki
https://doi.org/10.14341/osteo200632-6
Abstract
Insulin-like growth factor-1 (IGF-1), parathyroid hormone (PTH), biochemical markers of bone resorption and formation, bone mineral density (МПК) in spine and hip were determined in 46 recipients following heart transplantation (HI) and 79 -following kidney transplantation (KT) receiving triple immunosuppressive therapy. Serum IGF-1 in total recipients group (n=125) in mean was significantly lower then in health volunteers (187±102 and 250±51 ng/ml respectively; p<0,001). IGF-1 reduction was caused by glucocorticoids and cyclosporine hepatotoxicity and its level was associated with PTH level. Viral hepatitis and diabetes mellitus did not influence on IGF-1 level. There were significant inverse correlations between IGF-1 and МПК in recipients groups with normal PTH and without viral hepatitis and diabetes mellitus.
About the Authors
V P BuzulinaI A Pronchenko
N A Tomilina
R N Vedernikova
O N Rzhevskaya
I P Ermakova
References
1. Ермакова И.П., Пронченко И.А., Бузулина В.П., Томилина Н.А., Колиашвили Т.К., Хубутия М.Ш., Шумаков В.И. Остеопротегерин, инсулинподобный фактор роста-1 и биохимические маркеры обмена кости у больных с остеопатиями после пересадки почки и сердца // Остеопороз и остеопатии. 2004. № 2. С. 2-5.
2. Пронченко И.А., Бузулина В.П., Томилина Н.А., Ведерникова Р.Н., Ермакова И.П. Биохимические маркеры костного метаболизма и потерь костной ткани после аллотрансплантании трупной почки. Одномоментное исследование // Клин. Лаб. Диагностика. М., Медицина. 2005; 11: 3-8.
3. Canalis E., Giustino A. Glucocorticoid-induced osteoporosis: Summary of Workshop. // J. Clin. Endocrin.& Metabolism. 2001;Vol 86, №12: 5681-5685.
4. Gallego-Rojo F.J., Gonzalez-Calvin J.L., Munoz-Torres M., Mundi J.L., Fernandez-Perez R., Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis // Hepatology. 1998; 28 (3): 695-9.
5. Jehle P.M., Jehle D.R., Mohan S., Bohm B.O. Serum levels of insu lin-like growth factor system components and relationship to bone me tabolism in Type 1 and Type 2 diabetes mellitus patients // J Endocrinol. 1998; 159 (2): 297-306.
6. Jehle P.M., Ostertag A., Schulten K., Schulz W., Jehle D.R., Stracke S., Fiedler R., Deuber H.J., Keller F., Boehm B.O., Baylink D.J., Mohan S. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy // Kidney Int. 2000; 57 (2): 423-36.
7. Kemink S.A., Hermus A.R., Swinkels L.M., Lutterman J.A., Smals A.G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology // J Endocrinol Invest. 2000^3 (5): 295-303.
8. Leung К.С., Johannsson G., Leong G.M., Ho K.K. Estrogen regulation of growth hormone action // Endocr Rev. 2004;25 (5) : 693-721. Review.
9. Lopez-Calderon A., Soto L., Villanua M.A., Vidarte L., Martin A.I. The effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male rats // Life Sci. 1999;64 (17): 1473-83.
10. Maalouf N.M., Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab. 2005;90 (4): 2456-65. Review.
11. Malyszko J., Malyszko J.S., Wolozynski S., Mysliwiec M. Osteoprotegerin and its corelations with new markers of bone formation and bone resorption in kidney transplantation recipients // Transplantation proceeding. 2003, 35:2227-2229.
12. Mandla R., Midtvedt K., Line P.D., Hartmann A., Bergan S. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients // Transpl Int. 2006;19 (1) : 44-53.
13. Rosen C.J. Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications // Clin Chem. 1999;45 (8 Pt 2): 1384-90. Review.
14. Schiefke I., Fach A., Wiedmann M., Aretin A.V., Schenker E., Borte G., Wiese M., Moessner J. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis В or С infection // World J Gastroenterol. 2005; 11 (12): 1843-7.
15. Soto L., Martin A.I., Vara E., Lopez-Calderon A. Cyclosporin a treatment is able to revert the decrease in circulating GH and IGF-I and the increase in IGFBPs induced by adjuvant arthritis // Horm Metab Res. 2001; 33 (10): 590-5.
16. Soylemezoglu O., Derici U., Arinsoy T. Et al. Changes in bone mineral density, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in kidney transplant recipients. A longitudinal study // Nephron, 2002; 91 (3): 468-473.
17. Ueland T. GH/IGF-I and bone resorption in vivo and in vitro // Eur J Endocrinol. 2005; 152 (3): 327-32. Review.
18. Weber M.M., Auernhammer C.J., Lee P.D., Engelhardt D., Zachoval R. Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopic liver transplantation // Horm Res. 2002;57 (3-4): 105-12.
19. Zofkova I. Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism // Physiol Res. 2003;52 (6): 657-79. Review.
Review
For citations:
Buzulina V.P., Pronchenko I.A., Tomilina N.A., Vedernikova R.N., Rzhevskaya O.N., Ermakova I.P. Klinicheskie i biokhimicheskie aspekty issledovaniya insulinonodobnogo faktora rosta-1 v syvorotke krovi u retsipientov s narusheniyami kostnogo obmena posle peresadki serdtsa i pochki. Osteoporosis and Bone Diseases. 2006;9(3):2-6. (In Russ.) https://doi.org/10.14341/osteo200632-6
Views:
361
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
